#1 Clinical Trials Search in Europe

Iron Sucrose

Iron sucrose is an intravenous iron preparation used to treat iron deficiency anemia in various patient populations. This article summarizes key findings from clinical trials investigating the safety and efficacy of iron sucrose for treating anemia in conditions like chronic kidney disease, heart failure, and other iron-deficient states. We’ll explore how iron sucrose compares to other iron formulations and its potential benefits for improving anemia and quality of life in patients.

Table of Contents

What is Iron Sucrose?

Iron sucrose is a medication used to treat iron deficiency anemia, a condition where the body doesn’t have enough healthy red blood cells to carry oxygen effectively. It’s known by several brand names, including Venofer[1], Feriv[10], and in some cases, it may be compared to or used alongside other iron preparations like Monofer (iron isomaltoside)[9].

Conditions Treated with Iron Sucrose

Iron sucrose is primarily used to treat iron deficiency anemia in various patient groups, including:

  • Chronic Kidney Disease (CKD) patients, especially those on hemodialysis[1][7]
  • Heart Failure patients with anemia[1][7]
  • Inflammatory Bowel Disease (IBD) patients with iron deficiency[2]
  • Peritoneal Dialysis patients with iron deficiency anemia[9]
  • Patients with hip fractures to prevent perioperative anemia (anemia occurring around the time of surgery)[10]

How Iron Sucrose Works

Iron is essential for the production of hemoglobin, a protein in red blood cells that carries oxygen throughout the body. Iron sucrose provides iron in a form that can be easily used by the body to make hemoglobin. When you don’t have enough iron, your body can’t produce enough hemoglobin, leading to anemia[5].

How Iron Sucrose is Administered

Iron sucrose is typically given as an intravenous (IV) infusion, meaning it’s delivered directly into your bloodstream through a vein. The dosage and frequency can vary depending on your specific condition and needs. Some common administration methods include:

  • 200mg weekly for 5 weeks[1]
  • 300mg per infusion per week[2]
  • 500mg over one hour (in some studies investigating higher doses)[5]
  • 100mg weekly during the first hour of hemodialysis[8]

The exact dosage and schedule will be determined by your healthcare provider based on your individual needs and condition.

Efficacy of Iron Sucrose

Iron sucrose has been shown to be effective in treating iron deficiency anemia across various patient groups. Some key benefits include:

  • Improving hemoglobin levels[1][9]
  • Reducing the need for blood transfusions[10]
  • Improving quality of life and reducing fatigue in anemic patients[9]
  • Replenishing iron stores more effectively than oral iron supplements in some patient groups[2]

Safety and Side Effects

Iron sucrose is generally considered to have a good safety profile, especially compared to older iron preparations. However, like all medications, it can have side effects. Some potential side effects and safety considerations include:

  • Hypersensitivity reactions (allergic reactions)[6]
  • Gastrointestinal disturbances[9]
  • Changes in blood pressure[5]
  • Potential impact on oxidative stress in the body (still being studied)[2]

Your healthcare provider will monitor you closely during and after the infusion to watch for any adverse reactions.

Use in Special Populations

Iron sucrose has been studied and used in various special populations, including:

  • Older adults: Studies have looked at its use in older adults with unexplained anemia[4]
  • Patients with chronic kidney disease: It’s commonly used in this population, including those on dialysis[8]
  • Heart failure patients: It’s been studied for use in heart failure patients with anemia[1]

Ongoing Research

Research on iron sucrose is ongoing, with studies looking at various aspects of its use, including:

  • Comparing it to other iron preparations[9]
  • Investigating its effects on other markers in the body, such as FGF23 (a protein involved in phosphate regulation)[7]
  • Exploring its use in new patient populations or conditions[10]

These ongoing studies help to further our understanding of how iron sucrose can be used most effectively and safely to treat iron deficiency anemia in various patient groups.

Aspect Details
Primary Use Treatment of iron deficiency anemia
Patient Populations Chronic kidney disease, heart failure, inflammatory bowel disease, and other iron-deficient states
Administration Intravenous infusion, typically 100-300 mg doses
Efficacy Measures Improved hemoglobin levels, reduced transfusion needs, increased iron saturation
Safety Profile Generally well-tolerated; rare serious side effects include anaphylaxis
Comparative Studies Compared to oral iron, other IV iron formulations (e.g., iron isomaltoside)
Quality of Life Impact Potential improvements in fatigue, physical function, and overall well-being

FAQ

  • What is iron sucrose used for? Iron sucrose is primarily used to treat iron deficiency anemia in patients who cannot tolerate or do not respond well to oral iron supplements. It is commonly used in patients with chronic kidney disease, heart failure, inflammatory bowel disease, and other conditions associated with iron deficiency.
  • How is iron sucrose administered? Iron sucrose is administered intravenously, typically as an infusion over 15-60 minutes. The dose and frequency can vary depending on the patient's condition and iron needs, but common regimens include weekly doses of 100-300 mg.
  • What are the potential benefits of iron sucrose treatment? Potential benefits of iron sucrose treatment include improved hemoglobin levels, reduced need for blood transfusions, increased energy levels, improved physical function, and better quality of life for patients with iron deficiency anemia.
  • Are there any side effects associated with iron sucrose? While generally well-tolerated, some patients may experience side effects such as nausea, low blood pressure, or allergic reactions. Serious side effects are rare but can include anaphylaxis. Patients are typically monitored during and after infusions for any adverse reactions.
  • How does iron sucrose compare to other intravenous iron preparations? Iron sucrose has been shown to have a good safety profile compared to older iron formulations like iron dextran. It may require more frequent dosing than newer preparations like ferric carboxymaltose or iron isomaltoside, but it is generally considered effective and well-tolerated for treating iron deficiency anemia.

Ongoing Clinical Trials on Iron Sucrose

  • Study comparing ferumoxytol and iron sucrose for treating iron deficiency anemia in children

    Recruiting

    1 1 1 1
    Investigated drugs:
    Lithuania Poland

  • Comparing ferumoxytol and iron sucrose for treating iron deficiency anemia in children with chronic kidney disease

    Recruiting

    1 1 1 1
    Investigated drugs:
    Hungary Lithuania Poland

Glossary

  • Anemia: A condition in which you lack enough healthy red blood cells to carry adequate oxygen to your body's tissues, often causing fatigue and weakness.
  • Chronic Kidney Disease (CKD): A condition characterized by gradual loss of kidney function over time, often associated with anemia due to decreased production of erythropoietin.
  • Erythropoietin: A hormone produced by the kidneys that stimulates red blood cell production in the bone marrow.
  • Ferritin: A blood protein that contains iron and is the primary form of iron stored inside cells.
  • Hemoglobin: The protein in red blood cells that carries oxygen to tissues throughout the body.
  • Iron Deficiency: A condition in which the body doesn't have enough iron to produce hemoglobin, leading to anemia.
  • Iron Saturation: A measure of how much iron is bound to transferrin in the blood, used to assess iron status.
  • Transferrin: A protein that binds to iron and transports it through the blood.
  • Intravenous (IV): Administered directly into a vein.
  • Bioequivalence: The property of two drug products having the same biological effect in the body.

References

  1. https://clinicaltrials.gov/study/NCT00386126
  2. https://clinicaltrials.gov/study/NCT01067547
  3. https://clinicaltrials.gov/study/NCT00719459
  4. https://clinicaltrials.gov/study/NCT01309659
  5. https://clinicaltrials.gov/study/NCT02977611
  6. https://clinicaltrials.gov/study/NCT01151592
  7. https://clinicaltrials.gov/study/NCT03106298
  8. https://clinicaltrials.gov/study/NCT00560976
  9. https://clinicaltrials.gov/study/NCT03610230
  10. https://clinicaltrials.gov/study/NCT01084122